Ever since the S&P 500 dipped below the landmark support at 1060, it has become increasingly evident that the Federal Reserve, along with hedge funds, institutions and banks have been keen on playing games with retail investors in order to stir up false hopes that a recovery may be on the way. Well, guess what, [...]

Looks like the bulls will be frying on a wooden stick via the bears bond-fire as of early morning Tuesday, June, 29, 2010, especially considering the bloody massacre that took place in our World Markets: China and Europe. Fears on the World Bank’s statement that economic growth in China would slow caused panic worldwide, and [...]

With the continued pessimism on economic outlook and future data, there currently sits no better investment on the table other than Direxion Financial Bear 3x ETF (NYSE:FAZ), and the obvious choice, Gold ETF (NYSE:GLD). While numerous reports have surfaced recently that several polled Wall Street analysts foresee a rise of 13% in the S&P 500 [...]

It seems like the Feds and their relentless pursuit of a speedy economic recovery have pointed their direction towards the mass U.S. media in order to capitalize on the slow June trading month. Major banks rallied by the bunches, with the likes of Citigroup (NYSE:C), Bank of America (NYSE:BAC), JPMorgan Chase (NYSE:JPM), Goldman Sachs (NYSE:GS), [...]

The 3x Financial Bear ETF (NYSE:FAZ) has never looked so juicy, especially with the prepped up, fake financial rally created by sleazy, lying, and manipulative US government regulators as they issued numerous, erroneous headlines in order to hide the truth from the public’s eye. Bank stocks will be the first to feel the burn as [...]

Hana Biosciences, Inc. (OTC:HNAB) Comparisons: AspenBio Pharma (NASDAQ:APPY), Somaxon (NASDAQ:SOMX), Cell Therapeutics (NASDAQ:CTIC), Delcatch Systems (NASDAQ:DCTH). * Full article requires membership, visit our subscriptions page to become a member Amidst an uncertain market, Hana Biosciences has positioned itself nicely for the upcoming ASCO conference on June, 7th, 2010, where it will present its phase 2 [...]

Discovery Laboratories, Inc. This report is on (NASDAQ:DSCO), and also includes the following companies: Johnson & Johnson (NYSE:JNJ), Merck & Co. (NYSE:MRK), Pfizer (NYSE:PFE), Somaxon (NASDAQ:SOMX), Hemispherx (AMEX:HEB), AspenBio Pharma (NASDAQ:APPY), and AEterna Zentaris (NASDAQ:AEZS). Without a doubt, this past year the biotech industry has been characterised by companies who’ve found ways to persevere past [...]

AEterna Zentaris Inc. (NASDAQ:AEZS) The oncology focused companies, led by Dendreon (NASDAQ:DNDN) and Human Genome (NASDAQ:HGSI) have become the biotechnology and drugs sector’s hottest new fad, stealing the spotlight and making once average Joes trading in the $2 range, into, now, Hollywood stock market Broadway stars. With their names forged in stone for us to [...]

AspenBio Pharma, Inc. (Public, NASDAQ:APPY) AspenBio Pharma is about the embark on the most critical journey the company has ever faced since inception, with three important company developments awaiting announcements all within the next two weeks. At the forefront is the pivotal, stand alone 800 patient clinical trial result which is due in the first [...]

Provision Holding Inc (Public, OTC:PVHO) Provision Interactive announced several key company developments which should continue to help the company expand going forward. Amidst the rapidly growing 3D technology marketplace, this should be seen as exciting news for current and potential shareholders, as the company marches onwards into a highly profitable dominant player. Based on our [...]